Martin Heidecker, PhD
Director and Investment Manager, Boehringer Ingelheim Venture Fund
Dr. Heidecker joined the Boehringer Ingelheim Venture Fund in 2010 to invest in early innovative therapeutic life science companies. In October 2013, he established the US-office of BIVF in Cambridge, MA, where he is focusing on biotech seed-investments. Dr. Heidecker has 15 years of investing and commercial experience in both venture capital and global pharma companies. In addition to Sentien, he serves as board member of AMP Therapeutics in Leipzig, ArmaGen in Calabasas and 121bio in Cambridge. Prior to BIVF, Dr. Heidecker held several global roles in Marketing at Boehringer Ingelheim and Solvay Pharmaceuticals and was involved in the global launch of several products in the area of CNS. Dr. Heidecker began his career as an Investment Manager at Bayern Kapital, focusing on seed investments of biotech companies. He holds a PhD in Biology, as well as a MS in Biology and Economics. He serves on the board of AMP Therapeutics GmbH and ArmaGen Technologies, Inc.